Reuters logo
BRIEF-CymaBay announces positive interim results from low-dose phase 2 study of seladelpar
July 17, 2017 / 12:00 PM / 3 months ago

BRIEF-CymaBay announces positive interim results from low-dose phase 2 study of seladelpar

July 17 (Reuters) - Cymabay Therapeutics Inc:

* CymaBay announces positive interim results from its ongoing low-dose phase 2 study of seladelpar in patients with primary biliary cholangitis

* CymaBay Therapeutics Inc says strong reduction in alkaline phosphatase of 39pct (5 mg) and 45pct (10 mg) at week 12

* CymaBay Therapeutics Inc says FDA agrees to extend dosing of 5 mg and 10 mg beyond six months

* CymaBay Therapeutics Inc says potential for superior efficacy and better tolerability than existing second-line therapy in study

* CymaBay Therapeutics Inc says in study there were no serious adverse events and no safety transaminase signal was observed at either dose

* CymaBay Therapeutics Inc says fda has agreed to allow continuation of seladelpar treatment beyond six months for 5 mg and 10 mg doses Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below